Compounds > 4-butyrolactone
Page last updated: 2024-08-18

4-butyrolactone and Infarction, Middle Cerebral Artery

4-butyrolactone has been researched along with Infarction, Middle Cerebral Artery in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Liu, J; Mao, Z; Seto, S; Tian, L; Wang, G; Wang, N; Wang, Y; Wu, Q1
Chen, C; Du, JR; Duan, W; Gan, YM; Liu, DL; Yang, YX1
Chen, L; Fu, Y; Jiang, Z; Li, L; Ma, H; Ning, L; Qi, H; Yang, N; Yu, J; Zhao, Z; Zhu, H1
Alimoradi, H; Baery, N; Barzegar-Fallah, A; Barzegar-Fallah, N; Malekmohammadi, N; Parsa, A; Soleymankhani, M1
Maher, TJ; Quang, LS; Sadasivan, S1
Du, JR; Kuang, X; Liu, YX; Peng, HY; Qian, ZM; Wang, CY; Zhang, GY1

Other Studies

6 other study(ies) available for 4-butyrolactone and Infarction, Middle Cerebral Artery

ArticleYear
Ligustilide ameliorates hippocampal neuronal injury after cerebral ischemia reperfusion through activating PINK1/Parkin-dependent mitophagy.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 101

    Topics: 4-Butyrolactone; Animals; Brain Ischemia; Hippocampus; Infarction, Middle Cerebral Artery; Ischemic Stroke; Mammals; Mitophagy; Protein Kinases; Rats; Reperfusion; Reperfusion Injury; Ubiquitin-Protein Ligases

2022
Phthalide derivative CD21 alleviates cerebral ischemia-induced neuroinflammation: Involvement of microglial M2 polarization via AMPK activation.
    European journal of pharmacology, 2020, Nov-05, Volume: 886

    Topics: 4-Butyrolactone; AMP-Activated Protein Kinases; Animals; Behavior, Animal; Benzofurans; Brain Ischemia; Cell Line; Cell Polarity; Cytokines; Dose-Response Relationship, Drug; Encephalitis; Enzyme Activation; Infarction, Middle Cerebral Artery; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Phenotype; Psychomotor Performance

2020
Protective HSP70 Induction by Z-Ligustilide against Oxygen-Glucose Deprivation Injury via Activation of the MAPK Pathway but Not of HSF1.
    Biological & pharmaceutical bulletin, 2015, Volume: 38, Issue:10

    Topics: 4-Butyrolactone; Animals; Benzhydryl Compounds; Cell Survival; Glucose; HEK293 Cells; HSP70 Heat-Shock Proteins; Humans; Infarction, Middle Cerebral Artery; Male; MAP Kinase Signaling System; Neuroprotective Agents; Oxygen; PC12 Cells; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Reperfusion Injury; RNA, Small Interfering

2015
Kelussia odoratissima Mozaff attenuates thromboembolic brain injury, possibly due to its Z-ligustilide content.
    Brain injury, 2016, Volume: 30, Issue:7

    Topics: 4-Butyrolactone; Animals; Antioxidants; Apiaceae; Brain Edema; Catalase; Cerebral Cortex; Disease Models, Animal; Glutathione; Infarction, Middle Cerebral Artery; Male; Malondialdehyde; Oxidative Stress; Plant Extracts; Rats; Rats, Wistar; Stroke; Superoxide Dismutase; Tumor Necrosis Factor-alpha

2016
Gamma-Hydroxybutyrate (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion.
    Annals of the New York Academy of Sciences, 2006, Volume: 1074

    Topics: 4-Butyrolactone; Animals; Butylene Glycols; Cerebral Arterial Diseases; Infarction, Middle Cerebral Artery; Male; Rats; Rats, Sprague-Dawley; Sodium Oxybate

2006
Neuroprotective effect of Z-ligustilide against permanent focal ischemic damage in rats.
    Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:2

    Topics: 4-Butyrolactone; Animals; Body Temperature; Brain Edema; Brain Ischemia; Infarction, Middle Cerebral Artery; Male; Neurologic Examination; Neuroprotective Agents; Rats; Rats, Sprague-Dawley

2007